How to Avoid Desk Rejection at Pharmacology & Therapeutics (2026)
Avoid desk rejection at Pharmacology & Therapeutics by treating it as an invitation-gated review venue, not a normal cold-submission journal.
Associate Professor, Clinical Medicine & Public Health
Author context
Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.
Readiness scan
Find out if this manuscript is ready to submit.
Run the Free Readiness Scan before you submit. Catch the issues editors reject on first read.
How Pharmacology & Therapeutics is likely screening the manuscript
Use this as the fast-read version of the page. The point is to surface what editors are likely checking before you get deep into the article.
Question | Quick read |
|---|---|
Editors care most about | A pharmacology-centered review, not general disease biology |
Fastest red flag | Treating the journal like a standard cold-submission venue |
Typical article types | Invited review articles |
Best next step | Confirm that a viable invitation route exists |
Quick answer: the fastest path to Pharmacology & Therapeutics desk rejection is to treat the journal like a normal review-submission target when it is really an invitation-gated editorial venue.
That is the main practical reality. The current Elsevier guide for authors says Pharmacology & Therapeutics is a reviews journal, only publishes invited reviews, and does not accept proposals for review articles. That means the first desk question is usually not about formatting. It is whether the manuscript is realistically in bounds at all. Once that access question is resolved, editors then screen very specifically for reviews centered on drug actions, pharmacology, and drug targets, not broad disease-biology summaries with a therapeutic paragraph attached.
In our pre-submission review work with Pharmacology & Therapeutics candidates
In our pre-submission review work with Pharmacology & Therapeutics candidates, the most common early failure is owner-journal mismatch.
Authors often have a serious review topic and a competent draft. The problem is that the journal is not really open to them procedurally, or the review is built more around disease mechanism than around pharmacology. At that point, the manuscript can be strong and still be the wrong product for the journal.
The live journal materials make the triage logic fairly explicit:
- the journal publishes critical and authoritative reviews
- the editorial center is pharmacology, drug actions, and drug targets
- reviews are invited only
- proposals are not accepted
That combination means the desk screen is unusually harsh on mis-targeting. Many failures here happen before the journal even reaches a pure quality judgment.
Common desk rejection reasons at Pharmacology & Therapeutics
Reason | How to Avoid |
|---|---|
The journal is not actually open to the author through a real route | Confirm invitation or legitimate editorial path before drafting heavily |
The manuscript is more disease biology than pharmacology | Rebuild the narrative around drug actions, therapeutic mechanisms, or targets |
The review is descriptive rather than authoritative | Make clear judgments about the field instead of only summarizing it |
The article sounds broad but not editorially necessary | Explain why this review sharpens field thinking now |
The access route is left vague in the cover note | State the invitation or prior editor contact clearly and early |
The quick answer
To avoid desk rejection at Pharmacology & Therapeutics, make sure the project clears four tests.
First, you need a real route in. If you do not have an invitation path or legitimate editorial access point, the project is probably mis-targeted from the start.
Second, the review has to be truly pharmacology-centered. Disease pathophysiology is relevant here only when it serves a therapeutic and drug-target narrative.
Third, the manuscript has to be critical and authoritative. A polished literature tour is usually not enough.
Fourth, the article has to justify why this topic deserves a high-level pharmacology review slot now. Broad importance without editorial necessity usually reads soft.
If any of those four elements is weak, the paper is vulnerable before peer review becomes the main issue.
What Pharmacology & Therapeutics editors are usually deciding first
The first editorial decision at Pharmacology & Therapeutics is usually an access, pharmacology identity, and authority decision.
Is this manuscript realistically in bounds for an invited-review journal?
If the answer is unclear, the paper is already exposed.
Is the center of gravity really pharmacology?
Editors are not looking for general disease reviews with secondary therapeutic implications.
Does the manuscript take a strong critical stance?
The journal's positioning around authoritative reviews means summary alone is rarely enough.
Would a top pharmacology reader say this review belongs here rather than in a broader translational or disease journal?
That is often the real fit question.
That is why mis-targeting is so common here. Authors sometimes think they are solving a quality problem when the real problem is that the journal owner is wrong from the start.
Timeline for the Pharmacology & Therapeutics first-pass decision
Stage | What the editor is deciding | What you should have ready |
|---|---|---|
Cover note opening | Is there a real invitation path or editorial route? | A direct statement of invitation or prior editor contact |
Editorial identity screen | Is the review truly about pharmacology, drug actions, or targets? | A thesis centered on therapeutic mechanism |
Value screen | Is the manuscript authoritative rather than descriptive? | A draft that makes field-level judgments |
Send-out decision | Is this review strong enough for a flagship pharmacology review venue? | A credible authority case and a clear reason the topic matters now |
Three fast ways to get desk rejected
Some patterns recur.
1. Treating the journal like a standard review-submission venue
This is the biggest procedural mistake. If you do not have a real route in, the rest of the draft may not matter.
2. Writing disease biology with pharmacology language layered on top
The journal's public description is centered on drug action and drug targets. If the therapeutic narrative is not load-bearing, the fit weakens fast.
3. Summarizing the field instead of leading it
At this journal level, editors want a review that interprets, prioritizes, and resolves, not only one that covers the literature thoroughly.
Desk rejection checklist before you send Pharmacology & Therapeutics
Check | Why editors care |
|---|---|
The invitation route or editorial access path is explicit | This journal is not a routine cold-submission owner |
The core story is pharmacology, not only disease mechanism | Journal identity is a first-pass filter |
The draft makes real judgments about therapies or targets | Authoritative reviews need interpretation |
The author team's authority is clear | Review venues at this level screen for ownership credibility |
The topic explains why readers need this review now | Editorial priority matters even after access is solved |
Desk-reject risk
Run the scan while these rejection patterns are in front of you.
See which patterns your manuscript has before an editor does.
Submit if your manuscript already does these things
Your project is in better shape for Pharmacology & Therapeutics if the following are true.
You have a real invitation path or documented editorial route. Without that, the target is usually not practical.
The manuscript centers on pharmacology, drug actions, or drug targets. The disease context supports the pharmacology story rather than replacing it.
The review is clearly critical and authoritative. It helps readers understand what to believe, what to deprioritize, and where the therapeutic field is going.
The author team looks like a credible owner. That authority is legible from the package.
The topic belongs in a top pharmacology review venue. A serious reader would agree that this is the right editorial class.
When those conditions are true, the manuscript starts to look like a plausible Pharmacology & Therapeutics candidate rather than a strong review aimed at the wrong owner journal.
Think twice if these red flags are still visible
There are also some reliable warning signs.
Think twice if there is no actual invitation path. That is often enough on its own to stop the project here.
Think twice if the review reads like disease pathophysiology with a therapeutic appendix. The journal wants the opposite weighting.
Think twice if the manuscript catalogs the literature more than it interprets it. At this level, summary is not the main product.
Think twice if a different review venue would make the article look more naturally owned. That is often the right call commercially and editorially.
What tends to get through versus what gets rejected
The difference is usually not whether the science is respectable. It is whether the manuscript behaves like an invitation-class pharmacology review.
Papers that get through usually do three things well:
- they have a legitimate route into the journal
- they make pharmacology the central narrative
- they offer authoritative interpretation rather than broad summary
Papers that get rejected or are mis-targeted often fall into one of these patterns:
- no real invitation path
- disease review wearing pharmacology language
- comprehensive draft without enough judgment
That is why this journal can feel unforgiving. The desk screen is partly a quality screen, but first it is an availability and owner-journal screen.
Pharmacology & Therapeutics versus nearby alternatives
This is often the real fit decision.
Pharmacology & Therapeutics works best when the manuscript is invitation-class, pharmacology-centered, and built around therapeutic mechanism or drug-target interpretation.
A broader pharmacology review venue may be better when the topic is strong but the access model here is unrealistic.
A translational medicine review journal may be better when disease biology and clinical bridge are more central than pharmacology itself.
A disease-specific review journal may be better when the natural readership is one specialty field rather than the wider pharmacology audience.
That distinction matters because many desk failures here are target-selection failures in disguise.
The page-one test before submission
Before sending anything, ask:
Can an editor tell, in under two minutes, that this manuscript has a legitimate route into the journal, that the story is truly about pharmacology, and that the review will give an authoritative therapeutic interpretation rather than a broad summary?
If the answer is no, the manuscript is vulnerable.
For this journal, page one should make four things obvious:
- the access route
- the pharmacology center of gravity
- the authority of the review
- the reason the topic deserves this journal now
That is the real triage standard.
Common desk-rejection triggers
- no legitimate invitation path
- topic is more disease biology than pharmacology
- descriptive rather than authoritative review
- weak explanation of why this venue is the right owner
A Pharmacology & Therapeutics fit check can flag those first-read problems before you invest more drafting time.
For cross-journal comparison after the canonical page, use the how to avoid desk rejection journal hub.
Frequently asked questions
The most common reasons are that authors treat the journal like a normal cold-submission review venue, the topic is more disease biology than pharmacology, or the manuscript summarizes literature instead of making an authoritative therapeutic argument.
Editors usually decide whether the manuscript is realistically in bounds for an invitation-gated review journal and whether the core narrative is truly about pharmacology, drug actions, or drug targets.
No. The current Elsevier guide for authors says the journal only publishes invited reviews and that proposals for review articles are not accepted.
The biggest first-read mistake is investing in a full review draft before confirming you actually have an invitation path into the journal.
Sources
Before you upload
Choose the next useful decision step first.
Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.
Use the scan once the manuscript and target journal are concrete enough to evaluate.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Same journal, next question
Supporting reads
Conversion step
Choose the next useful decision step first.
Use the scan once the manuscript and target journal are concrete enough to evaluate.